ARWR241220C30000
- 0.50
- -0.29-36.71%
Arrowhead Pharmaceuticals Newsroom
Bernstein Maintains Market Perform on Arrowhead Pharma, Lowers Price Target to $24
Analysts' Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR) and Sanofi (OtherSNYNF)
Arrowhead Pharmaceuticals Is Maintained at Neutral by Citigroup
RBC Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $42
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Cuts Target Price to $45
A Quick Look at Today's Ratings for Arrowhead Pharmaceuticals(ARWR.US), With a Forecast Between $26 to $45
Arrowhead Pharma Analyst Ratings
Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target
RBC Capital Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)
Hold Rating on Arrowhead Pharmaceuticals: Balancing Strategic Advancements With Execution Risks
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $60
Arrowhead Pharmaceuticals Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
Arrowhead Pharma Analyst Ratings
Arrowhead Pharmaceuticals' Potential Approval of Clozasiran Drives Buy Rating and $60 Price Target
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $62
Piper Sandler Sticks to Its Buy Rating for Arrowhead Pharmaceuticals (ARWR)
Citi Maintains Arrowhead Pharmaceuticals(ARWR.US) With Hold Rating, Maintains Target Price $27
Arrowhead Pharma Analyst Ratings
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $60
Buy Rating Justified by Arrowhead Pharmaceuticals' Advancements in CNS-Targeted RNAi Therapeutics